NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome

Vancheswaran Gopalakrishnan(AstraZeneca (United States)), Glenda Lassi(AstraZeneca (United Kingdom)), Christopher Morehouse, Maria G. Belvisi(Lung Institute), Carolina Caceres(AstraZeneca (United States)), Antonio DiGiandomenico(AstraZeneca (South Korea)), Karl J. Staples(University Hospital Southampton NHS Foundation Trust), Tara Kenny(United States Army Medical Research Institute of Infectious Diseases), Arnita Barnes(AstraZeneca (United States)), Ventzislava A. Hristova(AstraZeneca (United States)), Jérôme Bouquet(University of California, San Francisco), Kristoffer Ostridge(Southampton General Hospital), Lisa Öberg(AstraZeneca (Sweden)), Alexey Ruzin(AstraZeneca (United States)), Natalie R. van Zuydam(AstraZeneca (United States)), Matthew S. Glover, Michael Hühn(AstraZeneca (Sweden)), Susan J. Wilson(Health Canada), Steven Novick(Quantitative BioSciences), Paul Warrener(AstraZeneca (United States)), Christine Tkaczyk(AstraZeneca (France)), Bret R. Sellman(AstraZeneca (United States)), Daniel Muthas(AstraZeneca (Sweden)), Raghothama Chaerkady(Johns Hopkins University), Christopher McCrae(AstraZeneca (United States)), Margaret Kehl(AstraZeneca (United States)), Tom Wilkinson(University Hospital Southampton NHS Foundation Trust), Tianhui Zhang(Chinese Academy of Sciences), Sonja Hess(Western Human Nutrition Research Center), B. Angermann(AstraZeneca (Sweden)), Adam Platt(AstraZeneca (United Kingdom)), Junmin Wang(Quantitative BioSciences), Jung Hwan Kim(AstraZeneca (United States)), Harini Shandilya(AstraZeneca (United States)), Ben Sparklin(AstraZeneca (United States)), Bairu Zhang
Respiratory Research
January 30, 2025
Cited by 4


Related Papers